The effect of rosiglitazone on overweight subjects with type 1 diabetes

Suzanne M. Strowig, Philip Raskin

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

OBJECTIVE- To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS- A total of 50 adult type 1 diabetic subjects with a baseline BMI ≥ 27 kg/m2 were randomly assigned in a double-blind fashion to take insulin and placebo (n = 25) or insulin and rosiglitazone 4 mg twice daily (n = 25) for a period of 8 months. Insulin regimen and dosage were modified in all subjects to achieve near-normal glycemic control. RESULTS- Both groups experienced a significant reduction in HbA1c (AlC) level (rosiglitazone: 7.9 ± 1.3 to 6.9 ± 0.7%, P < 0.0001; placebo: 7.7 ± 0.8 to 7.0 ± 0.9%, P = 0.002) and a significant increase in weight (rosiglitazone: 97.2 ± 11.8 to 100.6 ± 16.0 kg, P = 0.008; placebo: 96.4 ± 12.2 to 99.1 ± 15.0, P = 0.016). Baseline measures of BMI (P = 0.001), total daily insulin dose (P = 0.002), total cholesterol (P = 0.005), HDL cholesterol (P = 0.001), and LDL cholesterol (P = 0.02) were predictors of improvement in A1C level only in the group treated with rosiglitazone. Total daily insulin dose increased in subjects taking placebo (74.0 ± 33.8 to 82.0 ± 48.9 units, P < 0.05 baseline vs. week 32), but it decreased slightly in subjects taking rosiglitazone (77.5 ± 28.6 to 75.3 ± 33.1 units). Both systolic blood pressure (137.4 ± 15.6 vs. 128.8 ± 14.8 mmHg, baseline vs. week 32, P < 0.02) and diastolic blood pressure (87.2 ± 9.4 vs. 79.4 ± 7.2 mmHg, P < 0.0001) improved in the group treated with rosiglitazone. The total incidence of hypoglycemia did not differ between groups. CONCLUSIONS- Rosiglitazone in combination with insulin resulted in improved glycemic control and blood pressure without an increase in insulin requirements, compared with insulin- and placebo-treated subjects, whose improved glycemic control required an 11% increase in insulin dose. Weight gain and hypoglycemia were similar in both groups at the end of the study. The greatest effect of rosiglitazone occurred in subjects with more pronounced markers of insulin resistance.

Original languageEnglish (US)
Pages (from-to)1562-1567
Number of pages6
JournalDiabetes Care
Volume28
Issue number7
DOIs
StatePublished - Jul 2005

Fingerprint

rosiglitazone
Type 1 Diabetes Mellitus
Insulin
Placebos
Blood Pressure
Hypoglycemia

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The effect of rosiglitazone on overweight subjects with type 1 diabetes. / Strowig, Suzanne M.; Raskin, Philip.

In: Diabetes Care, Vol. 28, No. 7, 07.2005, p. 1562-1567.

Research output: Contribution to journalArticle

Strowig, Suzanne M. ; Raskin, Philip. / The effect of rosiglitazone on overweight subjects with type 1 diabetes. In: Diabetes Care. 2005 ; Vol. 28, No. 7. pp. 1562-1567.
@article{bfc1022f33d54648b874e4821b96863d,
title = "The effect of rosiglitazone on overweight subjects with type 1 diabetes",
abstract = "OBJECTIVE- To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS- A total of 50 adult type 1 diabetic subjects with a baseline BMI ≥ 27 kg/m2 were randomly assigned in a double-blind fashion to take insulin and placebo (n = 25) or insulin and rosiglitazone 4 mg twice daily (n = 25) for a period of 8 months. Insulin regimen and dosage were modified in all subjects to achieve near-normal glycemic control. RESULTS- Both groups experienced a significant reduction in HbA1c (AlC) level (rosiglitazone: 7.9 ± 1.3 to 6.9 ± 0.7{\%}, P < 0.0001; placebo: 7.7 ± 0.8 to 7.0 ± 0.9{\%}, P = 0.002) and a significant increase in weight (rosiglitazone: 97.2 ± 11.8 to 100.6 ± 16.0 kg, P = 0.008; placebo: 96.4 ± 12.2 to 99.1 ± 15.0, P = 0.016). Baseline measures of BMI (P = 0.001), total daily insulin dose (P = 0.002), total cholesterol (P = 0.005), HDL cholesterol (P = 0.001), and LDL cholesterol (P = 0.02) were predictors of improvement in A1C level only in the group treated with rosiglitazone. Total daily insulin dose increased in subjects taking placebo (74.0 ± 33.8 to 82.0 ± 48.9 units, P < 0.05 baseline vs. week 32), but it decreased slightly in subjects taking rosiglitazone (77.5 ± 28.6 to 75.3 ± 33.1 units). Both systolic blood pressure (137.4 ± 15.6 vs. 128.8 ± 14.8 mmHg, baseline vs. week 32, P < 0.02) and diastolic blood pressure (87.2 ± 9.4 vs. 79.4 ± 7.2 mmHg, P < 0.0001) improved in the group treated with rosiglitazone. The total incidence of hypoglycemia did not differ between groups. CONCLUSIONS- Rosiglitazone in combination with insulin resulted in improved glycemic control and blood pressure without an increase in insulin requirements, compared with insulin- and placebo-treated subjects, whose improved glycemic control required an 11{\%} increase in insulin dose. Weight gain and hypoglycemia were similar in both groups at the end of the study. The greatest effect of rosiglitazone occurred in subjects with more pronounced markers of insulin resistance.",
author = "Strowig, {Suzanne M.} and Philip Raskin",
year = "2005",
month = "7",
doi = "10.2337/diacare.28.7.1562",
language = "English (US)",
volume = "28",
pages = "1562--1567",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "7",

}

TY - JOUR

T1 - The effect of rosiglitazone on overweight subjects with type 1 diabetes

AU - Strowig, Suzanne M.

AU - Raskin, Philip

PY - 2005/7

Y1 - 2005/7

N2 - OBJECTIVE- To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS- A total of 50 adult type 1 diabetic subjects with a baseline BMI ≥ 27 kg/m2 were randomly assigned in a double-blind fashion to take insulin and placebo (n = 25) or insulin and rosiglitazone 4 mg twice daily (n = 25) for a period of 8 months. Insulin regimen and dosage were modified in all subjects to achieve near-normal glycemic control. RESULTS- Both groups experienced a significant reduction in HbA1c (AlC) level (rosiglitazone: 7.9 ± 1.3 to 6.9 ± 0.7%, P < 0.0001; placebo: 7.7 ± 0.8 to 7.0 ± 0.9%, P = 0.002) and a significant increase in weight (rosiglitazone: 97.2 ± 11.8 to 100.6 ± 16.0 kg, P = 0.008; placebo: 96.4 ± 12.2 to 99.1 ± 15.0, P = 0.016). Baseline measures of BMI (P = 0.001), total daily insulin dose (P = 0.002), total cholesterol (P = 0.005), HDL cholesterol (P = 0.001), and LDL cholesterol (P = 0.02) were predictors of improvement in A1C level only in the group treated with rosiglitazone. Total daily insulin dose increased in subjects taking placebo (74.0 ± 33.8 to 82.0 ± 48.9 units, P < 0.05 baseline vs. week 32), but it decreased slightly in subjects taking rosiglitazone (77.5 ± 28.6 to 75.3 ± 33.1 units). Both systolic blood pressure (137.4 ± 15.6 vs. 128.8 ± 14.8 mmHg, baseline vs. week 32, P < 0.02) and diastolic blood pressure (87.2 ± 9.4 vs. 79.4 ± 7.2 mmHg, P < 0.0001) improved in the group treated with rosiglitazone. The total incidence of hypoglycemia did not differ between groups. CONCLUSIONS- Rosiglitazone in combination with insulin resulted in improved glycemic control and blood pressure without an increase in insulin requirements, compared with insulin- and placebo-treated subjects, whose improved glycemic control required an 11% increase in insulin dose. Weight gain and hypoglycemia were similar in both groups at the end of the study. The greatest effect of rosiglitazone occurred in subjects with more pronounced markers of insulin resistance.

AB - OBJECTIVE- To evaluate the safety and effectiveness of rosiglitazone in the treatment of overweight subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS- A total of 50 adult type 1 diabetic subjects with a baseline BMI ≥ 27 kg/m2 were randomly assigned in a double-blind fashion to take insulin and placebo (n = 25) or insulin and rosiglitazone 4 mg twice daily (n = 25) for a period of 8 months. Insulin regimen and dosage were modified in all subjects to achieve near-normal glycemic control. RESULTS- Both groups experienced a significant reduction in HbA1c (AlC) level (rosiglitazone: 7.9 ± 1.3 to 6.9 ± 0.7%, P < 0.0001; placebo: 7.7 ± 0.8 to 7.0 ± 0.9%, P = 0.002) and a significant increase in weight (rosiglitazone: 97.2 ± 11.8 to 100.6 ± 16.0 kg, P = 0.008; placebo: 96.4 ± 12.2 to 99.1 ± 15.0, P = 0.016). Baseline measures of BMI (P = 0.001), total daily insulin dose (P = 0.002), total cholesterol (P = 0.005), HDL cholesterol (P = 0.001), and LDL cholesterol (P = 0.02) were predictors of improvement in A1C level only in the group treated with rosiglitazone. Total daily insulin dose increased in subjects taking placebo (74.0 ± 33.8 to 82.0 ± 48.9 units, P < 0.05 baseline vs. week 32), but it decreased slightly in subjects taking rosiglitazone (77.5 ± 28.6 to 75.3 ± 33.1 units). Both systolic blood pressure (137.4 ± 15.6 vs. 128.8 ± 14.8 mmHg, baseline vs. week 32, P < 0.02) and diastolic blood pressure (87.2 ± 9.4 vs. 79.4 ± 7.2 mmHg, P < 0.0001) improved in the group treated with rosiglitazone. The total incidence of hypoglycemia did not differ between groups. CONCLUSIONS- Rosiglitazone in combination with insulin resulted in improved glycemic control and blood pressure without an increase in insulin requirements, compared with insulin- and placebo-treated subjects, whose improved glycemic control required an 11% increase in insulin dose. Weight gain and hypoglycemia were similar in both groups at the end of the study. The greatest effect of rosiglitazone occurred in subjects with more pronounced markers of insulin resistance.

UR - http://www.scopus.com/inward/record.url?scp=21544439039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21544439039&partnerID=8YFLogxK

U2 - 10.2337/diacare.28.7.1562

DO - 10.2337/diacare.28.7.1562

M3 - Article

C2 - 15983301

AN - SCOPUS:21544439039

VL - 28

SP - 1562

EP - 1567

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 7

ER -